Utilizing the ImmuBridge™️ platform, we are capable of designing and developing trispecific antibodies that specifically target a spectrum of immune and tumor cell surface antigens, catering to a wide array of requirements within the realm of cancer therapeutic applications.

With the ImmunBridge™️ platform, we can design and develop bispecific T cell engagers (BiTEs) targeting specific tumor antigens to achieve precise targeting of cancer cells and effective therapeutics.

Based on the ImmuBridge™️ platform, we can design and develop multispecific antibodies targeting a range of T cell surface molecules and tumor surface antigens to meet diverse requirements in cancer therapeutic applications.

A wide range of cost-effective animal models, from Drosophila to non-human primates, from knockout models to different disease models, are released. In a pioneering effort to revolutionize life science research, a wide range of cost-effective animal disease models, from Drosophila to non-human primates, from knockout models to different disease models, are released. These groundbreaking...

Protheragen offers a variety of CAR-T cell therapy services, including personalized CAR-T cell analysis and therapy regimens based on a variety of disease models. Protheragen is an advanced CAR-T cell therapy service provider. With its extensive experience in cell therapy development and EndureCART™ technology platform, Protheragen provides investigators a wide range of disease models to...

Cell-based model is a crucial tool widely used in the early stage of drug development, which is a generalized modular approach to simulate the disease pathogenesis and detect drug response in vitro in biomedical research of rare diseases. Our company provides multiple approaches and in-depth solutions to help you speed up the development of cell-based models in rare...

Protheragen, a leading biotechnology company specializing in innovative research solutions, announces its comprehensive service portfolio dedicated to rare cancers, addressing the unique challenges these uncommon malignancies present to the medical community and affected patients worldwide. Rare cancers, often referred to as rare cancers, encompass a diverse group of approximately 200...